Health Horizons Future Healthcare Forum
At Cambridge Corn Exchange
2 Wheeler St, Cambridge CB2 3QB, UK
Follow Prof. Patrizia Paterlini Brechot, Founder & CSO of Rarecells Diagnostics, in the panel discussion "Prevention, early detection and future therapies in oncology" at Health Horizons Future Healthcare Forum in Cambridge Innovation Forum Find out more here: https://www.horizons.health/
"Patrizia, la nemica del Male"
The Italian newspaper "La Nazione" dedicated a long article to Prof. Patrizia Paterlini-Bréchot's nomination for the European Inventors Awards in the category "Research" and to its invention the ISET Technique.
RARECELLS DIAGNOSTICS Announces That Its Founder and Scientific Advisor, Professor Patrizia Paterlini-Bréchot, Is Named European Inventor Award 2019 Finalist
PARIS, May 7, 2019 -- Rarecells Diagnostics, a leading company in the field of Liquid Biopsy, announces today that the European Patent Office (EPO) has nominated Professor Patrizia Paterlini-Bréchot, as one of the three finalists of the European Inventor Award 2019 - category "Research"- for developing ISET®, a new diagnostic blood test for cancer (www.isetbyrarecells.com). The highly-sensitive ISET® test detects circulating tumour cells which play a key role in spreading cancer to other organs. ISET® opens up new avenues in predictive medicine and could save many lives.
"We know that with cancer treatment effective detection is a key," said EPO President António Campinos, announcing the European Inventor Award finalists. "Early diagnostic methods such as Patrizia Paterlini-Bréchot's invention are opening up a new front in the battle against this disease by helping doctors to detect the presence of a tumour in its very early stages," he declared. With an estimated 18.1 million new cancer diagnoses worldwide in 2018 and 9.6 million deaths, finding an effective, non-invasive way to diagnose cancers early on has the potential to save millions of lives.
Davide Bréchot, Deputy Director and CTO of Rarecells Diagnostics commented: "We are proud of this nomination. Since ISET® is valid for all types of solid cancers and most leukemias, we are now developing fast-track revolutionary cancer-specific ISET® tests and planning clinical trials to establish guidelines for the medical community."
The global Circulating Tumor Cells diagnostics market was estimated at EUR 8.2 billion in 2017 and is expected to grow to EUR 24.9 billion by 2023. Rarecells Diagnostics is a pioneer and leader in this market. ISET® has been validated by more than 70 independent scientific publications on over 2 000 patients and more than 600 cancer-free individuals.
About European Patent Office (EPO)
EPO is one of the largest public service institutions in Europe and the world's leading authority in patent searching. EPO examines about 160 000 patent applications every year. Through EPO patent granting, inventors are able to obtain high-quality patent protection covering a market of some 700 million people.
About RARECELLS DIAGNOSTICS
Rarecells Diagnostics is the exclusive licensee of the ISET® patent portfolios owned by Paris Descartes University, INSERM and Assistance Publique-Hôpitaux de Paris. The company develops high value, innovative diagnostic tests in the field of Liquid Biopsy www.rarecells.com
Molecular Medicine TRI-CON
At Moscone South Convention Center
San Francisco, California
Rarecells Diagnostics is a corporate support sponsor of CHI’s Molecular Medicine Tri-Conference taking place on March 10-15, 2019 in San Francisco.
Our guests can attend at a $200 discount* when registering online with keycode RAE200.
*This applies to new registrations and can’t be combined with any other offer. Not valid on short course only registrations.